Lumeda is a medical technology company advancing PDT to treat NSCLC and other thoracic malignancies. The company applies advanced photonics and proprietary artificial intelligence (AI) software to automate and digitize PDT light delivery to improve physician control, reduce procedure time and enable data capture for treatment planning. The multidisciplinary Lumeda team has decades of experience in the photonics industry, with expertise in systems engineering and commercialization of new technology.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/08/21 | $4,300,000 | Series A |
Connecticut Innovations Cycle Venture Partners | undisclosed |
